Co-Authors
This is a "connection" page, showing publications co-authored by BING Z CARTER and GAUTAM BORTHAKUR.
Connection Strength
0.458
-
XIAP antisense therapy with AEG 35156 in acute myeloid leukemia. Expert Opin Investig Drugs. 2013 May; 22(5):663-70.
Score: 0.111
-
XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38- cells in a phase 1/2 study of patients with relapsed/refractory AML. Apoptosis. 2011 Jan; 16(1):67-74.
Score: 0.095
-
Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community. Leukemia. 2024 Oct; 38(10):2073-2084.
Score: 0.061
-
TP53 Y220C mutations in patients with myeloid malignancies. Leuk Lymphoma. 2024 Oct; 65(10):1511-1515.
Score: 0.060
-
Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia. Cancer. 2024 Aug 01; 130(15):2652-2659.
Score: 0.059
-
Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. Blood Adv. 2021 08 24; 5(16):3163-3173.
Score: 0.050
-
Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. J Clin Oncol. 2009 Oct 01; 27(28):4741-6.
Score: 0.021